Machine signal
Active cluster sell — 8 distinct insiders, $224.6M, window ends Nov 17, 2026.
Figures computed from official regulatory filings — .
Analysttarget 50.82 USD (+31%) · consensus 4.54/5 · 11 buy · 2 hold · 0 sell
Ownershipinsiders 23.1% · institutions 80.86% · short 8.5% of float · 7.15d to cover
In USD · as of Nov 16, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Roivant Sciences Ltd. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Market information source · Nov 16, 2026
SEC company identity · Nov 16, 2026
Purchases and sales · full history
4 buys325 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| MANCHESTER KEITH S | Sell | $3.1M | SEC | ||
| Gold Daniel Allen | Sell | $20.1M | Unusual size | SEC | |
| QVT Financial LP | Sell | $21.6M | Unusual size | SEC | |
| Gold Daniel Allen | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| QVT Financial LP | Sell | $738K | SEC | ||
| Gold Daniel Allen | Sell | $5.1M | SEC | ||
| QVT Financial LP | Sell | $2.9M | SEC | ||
| QVT Financial LP | Sell | $3.1M | SEC | ||
| Gold Daniel Allen | Sell | $738K | SEC | ||
| MANCHESTER KEITH S | Sell | $21.6M | Unusual size | SEC | |
| QVT Financial LP | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| QVT Financial LP | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| QVT Financial LP | Sell | $30.5K | SEC | ||
| Gold Daniel Allen | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| MANCHESTER KEITH S | Sell | $5.1M | SEC | ||
| Gold Daniel Allen | Sell | $21.6M | Unusual size | SEC | |
| Gold Daniel Allen | Sell | $3.1M | SEC | ||
| MANCHESTER KEITH S | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Gold Daniel Allen | Sell | $30.5K | SEC | ||
| MANCHESTER KEITH S | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Gold Daniel Allen | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| MANCHESTER KEITH S | Sell | $20.1M | Unusual size | SEC | |
| QVT Financial LP | Sell | $20.1M | Unusual size | SEC | |
| Gold Daniel Allen | Sell | $2.9M | SEC | ||
| MANCHESTER KEITH S | Sell | $2.9M | SEC |